Medincell announces that analysis of a sub-group of patients undergoing first total knee arthroplasty shows positive phase 3 results.

Comparing patients treated with F14/mdc-CWM (a drug developed by Medincell in partnership with AIC - Arthritis Innovation Corporation) with those in the control group, the study revealed a 70% reduction in the number of opioid users and a 28% reduction in the total amount of opioids consumed in the first three months after surgery.

Patients treated with F14 also experienced 'a faster improvement in pain and range of motion in the knee, with significant results as early as six weeks after surgery', emphasizes Medincell.

These results testify to the effectiveness of the treatment in speeding up rehabilitation and reducing opioid consumption, a major issue in the USA.

Against this backdrop, Dr. Richard Malamut, Medincell's Medical Director, said that these data opened the way to future regulatory developments that could potentially complement standard treatments while reducing the use of opioids.

Copyright (c) 2024 CercleFinance.com. All rights reserved.